- 专利标题： Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
-
申请号： US15769295申请日： 2016-10-19
-
公开(公告)号： US10548899B2公开(公告)日： 2020-02-04
- 发明人: Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Masaki Ogino , Eiji Kimura , Masataka Murakami , Takuto Kojima , Jinichi Yonemori
- 申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 申请人地址： JP Osaka
- 专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人地址： JP Osaka
- 代理机构： Hamre, Schumann, Mueller & Larson, P.C.
- 优先权： JP2015-206780 20151020
- 国际申请： PCT/JP2016/081016 WO 20161019
- 国际公布： WO2017/069173 WO 20170427
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; A61K31/517 ; C07D403/06 ; C07D403/10 ; C07D405/14 ; C07D401/14 ; C07D239/88 ; C07D401/06 ; A61P25/28 ; A61P25/04 ; A61P25/18 ; A61P25/16
摘要：
The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
公开/授权文献
- US20180303841A1 HETEROCYCLIC COMPOUND 公开/授权日：2018-10-25
信息查询
